Dr. Zhukovsky has more than two decades experience in biotherapeutics research and development. He applies optimized monospecific- and novel bispecific-antibody platforms to the development of immunotherapeutics for cancer, with a particular focus on leveraging the biology of immune checkpoint modulators. He is a co-founder and partner at ZM Scientific LLC, a consultancy that advises biotechnology companies on the development of bispecific, optimized and native therapeutic antibodies, from discovery to the clinic.
Previously, Dr. Zhukovsky served as the chief scientific officer of Biomunex Pharmaceuticals, where he redirected the company’s strategic focus to immuno-oncology therapeutics by leveraging its bispecific antibody platform. Prior to that he served as the chief scientific officer of Affimed and held research positions at Boehringer Ingelheim, Xencor and other biotech companies. Dr. Zhukovsky received a Ph.D. in biochemistry from Brandeis University, and served his postdoctoral fellowship at Genentech.